Most Viewed Articles - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Most Viewed Articles

Pfizer Opens Online Pharmacy to Fight Counterfeit Medicine

May 6, 2013

Pfizer has launched a prescription-fulfillment website for Viagra tablets in an effort to combat the online sale of counterfeited medicine.

The New Normal In Biotech Financing

May 3, 2013

PTSM: Pharmaceutical Technology Sourcing and Management

Financing to biotech companies in North American and Europe declined in 2012 as debt funding decreased and the IPO market remained weak.

Big Pharma's Manufacturing Investments in Biologics

May 1, 2013

Pharmaceutical Technology

Despite overall manufacturing rationalization in the pharmaceutical/biopharmaceutical industry, the large pharmaceutical companies continue to invest in biologic-based manufacturing. The author provides an update in recent investment activity among the pharmaceutical majors in biologic-drug substance, vaccine, and parenteral drug manufacturing.

Pharmaceutical Technology and D&B Launch Business Marketplace

April 26, 2013

Pharmaceutical Technology has joined with Dun & Bradstreet Credibility Corp. to launch the Pharmaceutical Technology and BioPharm International Marketplace.

FDA Will Not Approve Generics to Original OxyContin

April 17, 2013

The FDA approved updated labeling for Purdue Pharma L.P.?s reformulated OxyContin tablets, but also determined that it will not approve generic versions of the original OxyContin.

Big Biotech Outpaces Big Pharma, Burrill Reports

April 17, 2013

Big Biotech companies are demonstrating they are better positioned than their pharmaceutical industry counterparts to meet changing demands.

Thermo Fisher Scientific to Acquire Life Technologies

April 16, 2013

$13.6 billion deal strengthens Thermo?s leading role.

Amgen to Pay $24.9 Million for False Claims Act Violations

April 16, 2013

Amgen Inc. has agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act.

Lilly Discontinues Phase III Rheumatoid Arthritis Program

February 12, 2013

ePT--the Electronic Newsletter of Pharmaceutical Technology

Eli Lilly and Co. announced that it will discontinue its Phase III rheumatoid arthritis program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, because of lack of efficacy.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here